title: Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury.
abstract: Acute liver failure (ALF) is a life threatening disease for which only few treatment options exist. The molecular pathways of disease progression are not well defined, but the death receptor Fas (CD95/Apo-1) appears to play a pivotal role in hepatocyte cell death and the development of ALF. Here, we explored posttranscriptional gene silencing of Fas by RNAi to inhibit pathophysiological gene expression. For targeting Fas expression in mice, Fas siRNA was formulated with the liver-specific siRNA delivery system DBTC. Treatment of mice with DBTC/siRNA(Fas) reduced Fas expression in the liver, but not in the spleen, lung, kidney or heart. Furthermore, silencing of Fas receptor was effective in blocking or reducing several aspects of ALF when it was tested in mice exposed to galactosamine/lipopolysaccharide (G/L), a well-known model of ALF. The application of DBTC/siRNA(Fas) 48 h prior G/L exposure resulted in amelioration of hepatic perfusion, reduction of hepatocellular death and increase of survival rate. The administration of DBTC/siRNA(Fas) formulation further diminished the inflammatory response upon G/L challenge, as indicated by a marked decrease of TNFα mRNA expression. However, IL-6 plasma concentration remained unaffectedly by DBTC/siRNA(Fas) formulation. Since the specific silencing of hepatic Fas expression only partially protected from inflammation, but completely attenuated apoptotic and necrotic cell death as well as microcirculatory dysfunction, the development of therapeutic strategies with DBTC lipoplex formulations to treat ALF should be combined with anti-inflammatory strategies to reach maximal therapeutic efficacy.
authors.affiliation: Institute for Experimental Surgery, Rostock University Medical Center, University of Rostock, Schillingallee 69a, 18057, Rostock, Germany, angela.kuhla@uni-rostock.de.
authors.forename: Angela
authors.initials: A
authors.lastname: Kuhla
authors.forename: Michael
authors.initials: M
authors.lastname: Thrum
authors.forename: Ute
authors.initials: U
authors.lastname: Schaeper
authors.forename: Volker
authors.initials: V
authors.lastname: Fehring
authors.forename: Ulf
authors.initials: U
authors.lastname: Schulze-Topphoff
authors.forename: Kerstin
authors.initials: K
authors.lastname: Abshagen
authors.forename: Brigitte
authors.initials: B
authors.lastname: Vollmar
mesh_terms: D000818:Animals; D017209:Apoptosis; D053222:Fas Ligand Protein / Q000235:genetics* / Q000378:metabolism; D005688:Galactosamine / Q000009:adverse effects*; D020868:Gene Silencing; D006801:Humans; D008070:Lipopolysaccharides / Q000009:adverse effects*; D008099:Liver / Q000166:cytology / Q000293:injuries* / Q000378:metabolism; D017114:Liver Failure, Acute / Q000209:etiology / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D019014:fas Receptor / Q000378:metabolism
chemical_list: D053222:Fas Ligand Protein; D008070:Lipopolysaccharides; D019014:fas Receptor; D005688:Galactosamine